Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder affecting millions worldwide. The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health’s AI-powered Cloudscreen drug repurposing platform, coupled with experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health secures rights, exclusive licensing for two anticancer drugs
- Cosmos Health secures exclusive distribution agreement with Virax Biolabs
- Cosmos Health appoints Dimitrios Trafalis as head of oncology
- Cosmos Health CEO, CFO collectively increase stake by 343,000 shares
- Cosmos Health files to sell common stock, warrants, no amount given